Disclosures for "FIREFISH Parts 1 and 2: 36-month safety and efficacy of risdiplam in Type 1 spinal muscular atrophy (SMA)")
-
The institution of Dr. Darras has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amicus. Dr. Darras has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus. The institution of Dr. Darras has received research support from National Institutes of Health/National Institute of Neurological Disorders and Stroke,. The institution of Dr. Darras has received research support from Slaney Family Fund for SMA. The institution of Dr. Darras has received research support from Spinal Muscular Atrophy Foundation. The institution of Dr. Darras has received research support from CureSMA. The institution of Dr. Darras has received research support from Working on Walking Fund . The institution of Dr. Darras has received research support from CHERISH, CS2/CS12 . The institution of Dr. Darras has received research support from Biogen for CS11. The institution of Dr. Darras has received research support from AveXis. The institution of Dr. Darras has received research support from Sarepta Pharmaceuticals. The institution of Dr. Darras has received research support from PTC Therapeutics. The institution of Dr. Darras has received research support from Roche. The institution of Dr. Darras has received research support from Santhera. The institution of Dr. Darras has received research support from Scholar Rock. The institution of Dr. Darras has received research support from Fibrogen. The institution of Dr. Darras has received research support from Summit. Dr. Darras has received publishing royalties from a publication relating to health care. Dr. Darras has received publishing royalties from a publication relating to health care.
-
Giovanni Baranello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Giovanni Baranello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Giovanni Baranello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AveXis. Giovanni Baranello has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Giovanni Baranello has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AveXis. Giovanni Baranello has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Giovanni Baranello has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AveXis. The institution of Giovanni Baranello has received research support from Great Ormond Street Hospital Charity.
-
Odile Boespflug-Tanguy has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Minoryx. Odile Boespflug-Tanguy has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Inventiva. Odile Boespflug-Tanguy has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for BLUEBIRD.
-
Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Affinia Therapeutics. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis Gene Therapy. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Day has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. Dr. Day has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Day has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Scholar Rock. Dr. Day has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avidity. Dr. Day has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Muscular Dystrophy Association. The institution of Dr. Day has received research support from Audentes. The institution of Dr. Day has received research support from Novartis Gene Therapy. The institution of Dr. Day has received research support from Biogen. The institution of Dr. Day has received research support from Cytokinetics. The institution of Dr. Day has received research support from Roche/Genentech. The institution of Dr. Day has received research support from Sanofi/Genzyme. The institution of Dr. Day has received research support from Sarepta. The institution of Dr. Day has received research support from Scholar Rock. Dr. Day has received intellectual property interests from a discovery or technology relating to health care.
-
Nicholas Deconinck has received personal compensation in the range of $500-$4,999 for serving as a Consultant for biogen. Nicholas Deconinck has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for roche. Nicholas Deconinck has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for avexis. Nicholas Deconinck has received publishing royalties from a publication relating to health care.
-
Andrea Klein has nothing to disclose.
-
Ricardo Masson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche, Biogen, Avexis. Ricardo Masson has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche, Biogen, Avexis.
-
Dr. Mazurkiewicz Beldzin has received personal compensation in the range of $0-$499 for serving as a Consultant for Biogen, . Dr. Mazurkiewicz Beldzin has received personal compensation in the range of $0-$499 for serving as a Consultant for Novartis. Dr. Mazurkiewicz Beldzin has received personal compensation in the range of $0-$499 for serving as a Consultant for Roche. Dr. Mazurkiewicz Beldzin has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Mazurkiewicz Beldzin has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.
-
Eugenio Mercuri has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta, Santhera, PTC, Pfizer, Roche, Biogen, Avexis Novartis, Scholar Rock, Cytokinetics. Eugenio Mercuri has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sarepta, Santhera, PTC, Pfizer, Roche, Biogen, Avexis Novartis. The institution of Eugenio Mercuri has received research support from biogen.
-
Kristy Rose has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Roche. Kristy Rose has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Kristy Rose has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Kristy Rose has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen.
-
Dmitry Vlodavets has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AveXis. Dmitry Vlodavets has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Dmitry Vlodavets has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dmitry Vlodavets has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dmitry Vlodavets has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Novartis. Dmitry Vlodavets has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche. Dmitry Vlodavets has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for PTC Therapeutics. Dmitry Vlodavets has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dmitry Vlodavets has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for PTC Therapeutics. Dmitry Vlodavets has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche.
-
Hui Xiong has nothing to disclose.
-
Edmar Zanoteli has nothing to disclose.
-
Muna El-Khairi has received personal compensation for serving as an employee of Roche Products Limited.
-
Marianne Gerber has received personal compensation for serving as an employee of Roche. Marianne Gerber has received stock or an ownership interest from F Hoffmann La Roche .
-
Dr. Gorni has received personal compensation for serving as an employee of Hoffman La Roche.
-
Heidemarie Kletzl has received personal compensation for serving as an employee of Hoffmann-La Roche.
-
Laura Palfreeman has received personal compensation for serving as an employee of Roche.
-
Angela Dodman has received personal compensation for serving as an employee of F. Hoffman-La Roche Ltd.
-
The institution of Laurent Servais has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Laurent Servais has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. The institution of Laurent Servais has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Avexis. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dynacure. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Audentes. The institution of Laurent Servais has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sarepta. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Santhera. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for RegenexBio. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Affinia. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Anagenesis. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Catabasis. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Evox. Laurent Servais has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lupin. Laurent Servais has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Fibrogen.